TY - JOUR
T1 - Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty
T2 - Insights from the DESERT cooperation
AU - De Luca, Giuseppe
AU - Verdoia, Monica
AU - Dirksen, Maurits T.
AU - Spaulding, Christian
AU - Kelbæk, Henning
AU - Schalij, Martin
AU - Thuesen, Leif
AU - Hoeven, Bas van der
AU - Vink, Marteen A.
AU - Kaiser, Christoph
AU - Musto, Carmine
AU - Chechi, Tania
AU - Spaziani, Gaia
AU - Diaz de la Llera, Luis Salvador
AU - Pasceri, Vincenzo
AU - Di Lorenzo, Emilio
AU - Violini, Roberto
AU - Suryapranata, Harry
AU - Stone, Gregg W.
PY - 2013/9
Y1 - 2013/9
N2 - Background: Several studies have found that among patients with ST-segment elevation myocardial infarction (STEMI) treated by thrombolysis, female sex is associated with a worse outcome. However, still controversial is the prognostic impact of gender in primary angioplasty, especially in the era of drug-eluting stents (DES). Therefore, the aim of this study was to investigate sex-related differences in clinical outcome in patients with STEMI treated with primary angioplasty with Bare-Metal Stent (BMS) orDES. Methods: Our population is represented by 6298 STEMI patients undergoing primary angioplasty and stent implantation included in the DESERT database. Follow-up data were collected from 3 to 6 years after primary angioplasty. Results: Female gender was observed in 1466 (23.2%) out of 6298 STEMI patients. Women were older (65.3±12.4 vs 59.3±11.4 years, p<0.001), with higher prevalence of diabetes (18.6% vs 14.5%, p<0.001), hypertension (52.4% vs 41.4%, p<0.001), slightly longer ischemia time (272±247 vs 258±220min, p=0.06). No difference was observed in terms of angiographic and procedural characteristics.Follow-up data were available at a mean of 1201±441 days. At long-term follow-up female gender was associated with a significantly higher rate of death (11.7% vs 8.5%, HR [95% CI]=1.45 [1.18-1.78], p<0.001), while no difference was observed in terms of reinfarction (HR [95% CI]=1.14 [0.89-1.45], p=0.3), ST (HR [95% CI]=1.12 [0.85-1.48], p=0.4), with similar temporal distribution (acute, subacute, late and very late) between male and female patients, and no difference in TVR (HR [95% CI]=1.11 [0.95-1.3], p=0.2, p=0.2). These results were confirmed in both patients receiving BMS or DES. The impact of female gender on mortality disappeared after correction for baseline confounding factors (HR [95% CI]=0.88 [0.71-1.09], p=0.25). Conclusions: This study shows that in patients with STEMI treated by primary angioplasty, female gender is associated with higher mortality rate in comparison with men, and this is mainly due to their higher clinical and angiographic risk profiles. In fact, female sex did not emerge as an independent predictor of mortality.
AB - Background: Several studies have found that among patients with ST-segment elevation myocardial infarction (STEMI) treated by thrombolysis, female sex is associated with a worse outcome. However, still controversial is the prognostic impact of gender in primary angioplasty, especially in the era of drug-eluting stents (DES). Therefore, the aim of this study was to investigate sex-related differences in clinical outcome in patients with STEMI treated with primary angioplasty with Bare-Metal Stent (BMS) orDES. Methods: Our population is represented by 6298 STEMI patients undergoing primary angioplasty and stent implantation included in the DESERT database. Follow-up data were collected from 3 to 6 years after primary angioplasty. Results: Female gender was observed in 1466 (23.2%) out of 6298 STEMI patients. Women were older (65.3±12.4 vs 59.3±11.4 years, p<0.001), with higher prevalence of diabetes (18.6% vs 14.5%, p<0.001), hypertension (52.4% vs 41.4%, p<0.001), slightly longer ischemia time (272±247 vs 258±220min, p=0.06). No difference was observed in terms of angiographic and procedural characteristics.Follow-up data were available at a mean of 1201±441 days. At long-term follow-up female gender was associated with a significantly higher rate of death (11.7% vs 8.5%, HR [95% CI]=1.45 [1.18-1.78], p<0.001), while no difference was observed in terms of reinfarction (HR [95% CI]=1.14 [0.89-1.45], p=0.3), ST (HR [95% CI]=1.12 [0.85-1.48], p=0.4), with similar temporal distribution (acute, subacute, late and very late) between male and female patients, and no difference in TVR (HR [95% CI]=1.11 [0.95-1.3], p=0.2, p=0.2). These results were confirmed in both patients receiving BMS or DES. The impact of female gender on mortality disappeared after correction for baseline confounding factors (HR [95% CI]=0.88 [0.71-1.09], p=0.25). Conclusions: This study shows that in patients with STEMI treated by primary angioplasty, female gender is associated with higher mortality rate in comparison with men, and this is mainly due to their higher clinical and angiographic risk profiles. In fact, female sex did not emerge as an independent predictor of mortality.
KW - Drug-eluting stent
KW - Female gender
KW - Primary angioplasty
UR - http://www.scopus.com/inward/record.url?scp=84881634098&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2013.05.024
DO - 10.1016/j.atherosclerosis.2013.05.024
M3 - Article
SN - 0021-9150
VL - 230
SP - 12
EP - 16
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -